Search for a command to run...
1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M,et.al; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. 2. Movila D, Seiman DD, Dragan SR. Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives. Biomedicines. 2025 Dec 30;14(1):81. 3. Padda IS, Mahtani AU, Parmar M. Sodium-glucose transport 2 (SGLT2) inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. Updated 2025 Sep 15. Available from: https://www.ncbi.nlm.nih.gov/books/NBK576405/ 4. Kao TW, Huang CC. Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure. Front Cardiovasc Med. 2022 Dec 20; 9:1086672. 5. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care. 2016 May;39(5):717-25. 6. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-39. 7. Ku EJ, Lee DH, Jeon HJ, Oh TK. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study. Diabetes Res Clin Pract. 2019 May; 151:65-73. 8. Hussain M, Atif M, Babar M, Akhtar L. Comparison of Efficacy and Safety Profile of Empagliflozin Versus Dapagliflozin as Add on Therapy in Type 2 Diabetic Patients. J Ayub Med Coll Abbottabad. 2021 Oct-Dec;33(4):593-597. 9. Crabtree TSJ, Bickerton A, Dhatariya K, Gallagher A, Elliott J, Adamson K, et al. Real-world cross-comparison of metabolic outcomes with different sodium-glucose co-transporter 2 inhibitors agents in adults with type 2 diabetes: results from the Association of British Clinical Diabetologists audit programme. Br J Diabetes. 2024;24(1):51–55. 10. Castellana M, Procino F, Sardone R, Trimboli P, Giannelli G. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020 Jun 13;19(1):87. 11. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020 Sep 19;396(10254):819-829. 12. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, McMurray JJV, Solomon SD. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022 Sep 3;400(10354):757-767 13. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. 14. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure with reduced ejection fraction (EMPEROR-Reduced). N Engl J Med. 2020;383(15):1413–24. 15. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER). N Engl J Med. 2022;387(12):1089–98. 16. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction (EMPEROR-Preserved). N Engl J Med. 2021;385(16):1451–61. 17. Dhana R, Aqel Y, Rawat A, Mahato A, Maali Abusal A, Munawar N, Wei CR, Amin A. Comparative Cardiovascular Outcomes of Dapagliflozin Versus Empagliflozin in Patients with Type 2 Diabetes: A Meta-Analysis. Cureus. 2025 May 4;17(5): e83449. 18. Bonnesen K, Heide-Jørgensen U, Christensen DH, Lash TL, Hennessy S, Matthews A, Pedersen L, Thomsen RW, Schmidt M. Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults with Treated Type 2 Diabetes: A Target Trial Emulation. Circulation. 2024 Oct 29;150(18):1401-1411. 19. Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, et al. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390(16): 1455-1466. 20. Von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43(41):4421-4432. 21. James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024;3(2): EVIDoa2300286 22. Bose D, Maurya M, Konwar M. Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus: A meta-analysis of landmark renal and cardiovascular outcome trials. Indian J Pharmacol. 2023 Mar-Apr;55(2):119-127 23. Kelly MS, Wang M, Drazner MH, de Lemos JA, Mentz RJ, et al. Association of SGLT2 Inhibitors with Cardiovascular, Kidney, and Safety Outcomes Among Patients with Diabetes and Chronic Kidney Disease: A Systematic Review and Meta-analysis. JAMA Cardiol. 2021;6(7):848-58. 24. Upadhyay A. SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback. Kidney360. 2024 May 1;5(5):771-782. 25. Usman MS, Khan MS, Butler J, Anker SD, Greene SJ, et al. Empagliflozin vs dapagliflozin in patients with heart failure: a real-world study. JAMA Netw Open. 2024;7(5): e2410462. 26. Velusamy S, Kumar SR. Safety and efficacy of dapagliflozin versus empagliflozin as add-on therapy in type 2 diabetes mellitus management. Indian J Physiol Pharmacol. 2025; 69:136-41. 27. Varshney A, Rawat R. Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India. Rev Assoc Med Bras (1992). 2023 Aug 14;69(8): e20230090.